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2Overview
 Describe CDC vaccine safety monitoring systems
 HPV vaccine safety monitoring as a case study
 Broader national and international vaccine safety monitoring and 
research efforts
CDC Vaccine Safety Monitoring Systems
Safety
is Part of 
Every
Vaccine
5Primary HHS organizations
engaged in vaccine safety 
activities
Health Resources 
and Services Admin 
(HRSA)
Food and Drug
Admin 
(FDA)
National Institutes 
of Health 
(NIH)
Dept of Health and 
Human Services 
(HHS)
National Vaccine 
Program (NVP)
Other agencies and groups:
DoD
DVA
IHS
Manufacturers
Advisory Committees:
NVAC
ACIP
VRBPAC
ACCV
NCEZID
DHQP
Immunization 
Safety Office 
(ISO)
Centers for Disease
Control and 
Prevention (CDC)
6Immunization
Safety 
Office
VAERS
CISA
VSD
3 core 
programs
CDC vaccine safety monitoring
VAERSVaccine Adverse Event Reporting System
CISA Clinical Immunization Safety Assessment Project
VSD Vaccine Safety Datalink 
Communication and response to inquiries 
is cross-cutting function
7Co-managed by
CDC and FDA
Vaccine
Adverse
Event 
Reporting 
System
+
http://vaers.hhs.gov
8Two Ways to Report
1.  PDF Form
 Information about patient, healthcare 
provider and reporter, AEs, vaccines, 
preexisting medical conditions
 Other information: date vaccinated, AE 
onset date, vaccine type, lot number, 
dose number
 Anyone can submit a report
 All reports accepted without judgment 
on causality
 CDC encourages reporting as soon as 
possible, but no time limit on reporting 
Demographics
Vaccine(s)
AE(s)
Direct link to PDF: https://vaers.hhs.gov/pdf/VAERSForm_Aug2019.pdf
9Two Ways to Report
2.  Online Form
preferred method
 Same fields as PDF form
 Step-by-step visual guidance
 Security and convenience
Direct link to online report form: https://vaers.hhs.gov/esub/index.jsp
Visual Navigation 
Through
Each Section
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Adverse events in the context of vaccine doses 
distributed for use in the United States
164.3 million non-flu vaccines*
distributed (2017)
 29,937 AE reports to VAERS
• 1 report for every 5,488 doses 
distributed
159.1 million flu vaccines 
distributed (2018-19 season)
 11,138 AE reports to VAERS
• 1 report for every 14,284 doses 
distributed
*DT, DTaP, DTaP-Hep B – IPV, DTaP-HIB, DTaP-IPV-HIB, DTaP-IPV, DTP, DTP-HIB, EIPV, HEP A (Ped), HEP A (Adult), HEP AB, Hep B (Adult), Hep B (Ped), HEPB-HIB, Hib, HPV, MCV4, Measles, MenB, MENING (MPSV4), MMR, MMRV, Mumps, Pertussis, PPV23 
(PNEUMO), PCV7, PCV 13, Rota, Rubella, Td, Tdap, TETANUS, Varicella, Zoster
1111
 Signs, symptoms, and diagnoses coded using Medical Dictionary for 
Regulatory Activities (MedDRA) terms
 Clinical review of reports (includes medical records when available):
• All serious1 reports
• Selected conditions of special interest
 Trends and patterns of reports
 Reporting rates
 Empirical Bayesian data mining to detect disproportional reporting for 
vaccine-adverse event pairings
1Based on the Code of Federal Regulations if one of the following is reported: death, life-threatening illness, hospitalization or prolongation of 
hospitalization, permanent disability, congenital anomaly or birth defect (FDA routinely reviews all serious reports)
VAERS monitoring: methods
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Vaccine Adverse Event Reporting System (VAERS)
Strengths
 National data 
 Accepts reports from anyone
 Rapidly detects safety signals 
 Can detect rare adverse events
 Data available to public
Limitations
 Reporting bias 
 Inconsistent data quality and 
completeness
 Lack of unvaccinated comparison group
 Generally cannot assess causality
• As a hypothesis generating system, VAERS identifies potential vaccine safety 
concerns that can be studied in more robust data systems
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VSD
Vaccine
Safety
Datalink
8 participating integrated 
healthcare organizations
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Vaccine Safety Datalink (VSD)
 Established in 1990 
 Collaboration between CDC and several integrated 
healthcare organizations 
 Medical care and demographic data on over 12 million 
persons per year 
 Links vaccination data to health outcome data
 Used for surveillance and research
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Birth and death 
certificate 
information & 
family linkage
Immunization 
recordsEnrollment and 
demographics
Linked by 
study IDs
Images created by Wilson Joseph, Megan Mitchell, Ananth, and Iga from the noun project
Outpatient and 
clinic visits
Emergency room 
visits
Procedure codes Hospital discharge 
diagnosis codes
VSD electronic files + chart review 
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VSD methods
 Traditional epidemiologic studies
–
–
–
–
Descriptive analyses (e.g., background rates, vaccination coverage)
Cohort
Case-control
Self-control
 Tree-temporal scan data mining
 Rapid Cycle Analysis (RCA) for near real-time monitoring
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A powerful surveillance tool
 Near real-time vaccine-safety monitoring (using sequential monitoring techniques)
 Employs an automated analysis of ICD-coded diagnoses from administrative data
Designed to detect statistical signals (values above specified statistical thresholds)
 When a statistical signal occurs, CDC conducts a series of further evaluations, 
including traditional epidemiologic methods
 Chart-confirmation of diagnoses to confirm or exclude cases as true incident cases is 
a key part of statistical signal assessment 
Not all statistical signals represent a true increase in risk for an adverse event
Rapid Cycle Analysis (RCA) in VSD
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CISA
Clinical
Immunization
Safety
Assessment
 assist U.S. healthcare 
providers with complex 
vaccine safety questions 
about their patients
CISAeval@cdc.gov†
 conduct clinical research
Vaccine safety monitoring
vaccine safety experts 
7 participating medical 
research centers*
*Boston Medical Center, MA; Cincinnati Children’s Hospital 
Medical Center, OH; Columbia University, NY; Duke University, 
NC; Johns Hopkins University, MD; Kaiser Permanente Northern 
California, CA; Vanderbilt University TN 
†More information about clinical consults available at: 
http://www.cdc.gov/vaccinesafety/Activities/CISA.html
Case study of HPV vaccine safety
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VAERS4vHPV*
*VAERS 4vHPV 
safety surveillance, 
JAMA
RCA 4vHPV, Vaccine
Reported AEs 
following 4vHPV, 
J Womens Health
-HPV vaccine and 
CRPS, Ebiomed
-VTE and 4vHPV, 
Vaccine
-4vHPV and non-
manufacturer 
pregnancy reports, 
Vaccine
-Vaccination and 
30-day mortality
Pediatrics
-Maternal 
and infant 
outcomes 
after HPV 
vaccine, 
Obset
Gynecol
- GBS and 
4vHPV, 
Vaccine
-POTS and 
HPV in 
VAERS, J 
Adol
Health
-Spontaneous 
abortion after 
inadvertent 
HPV 
vaccination, 
Obset Gynecol
-VAERS 4vHPV 
safety 
surveillance, 
Vaccine
-VAERS 2vHPV 
safety 
surveillance, 
Br J Clin Pharm
-POI and 
adolescent vac 
Pediatrics
-Type 1 
diabetes and 
HPV vaccine, 
Vaccine
-Safety of 
9vHPV among 
pregnant 
women in 
VAERS, 
Vaccine
VAERS 4vHPV** VAERS 9vHPV
VSD 9vHPV RCA VSD 4vHPV RCA 
2011 2012 2013 2014 2015 2016 2017 2018 2019 20202009June 
2006
Safety Monitoring
Safety Studies
Timeline of CDC/ISO HPV vaccine safety monitoring 
and selected publications
21
Monitoring a recent vaccine: 9vHPV in VAERS and VSD
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Top 10 reported signs and symptoms1 after 9vHPV 
in VAERS, Dec 2014-Dec 2017 
Non-serious  (n=7,058) N (%) 
Dizziness 529 (7)
Syncope 488 (7)
Headache 355 (5)
Injection site pain 316 (4)
Injection site erythema 314 (4)
Nausea 313 (4)
Pyrexia (fever) 283 (4)
Loss of consciousness 273 (4)
Injection site swelling 266 (4)
Pallor 235 (3)
1 As coded using the MedDRA preferred terms (PT);  more than one code may be assigned to a single event
2 Based on the Code of Federal Regulations if one of the following is reported: death, life-threatening illness, hospitalization or prolongation of hospitalization or permanent disability
Serious2 (n=186) N (%)
Headache 63 (34)
Dizziness 50 (27)
Nausea 48 (26)
Fatigue 42 (23)
Pyrexia (fever) 35 (19)
Asthenia (weakness) 34 (18)
Vomiting 33 (18) 
Syncope 29 (16)
Abdominal pain 26 (14)
Loss of consciousness 26 (14)
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VAERS Empirical Bayesian data mining for 9vHPV
 Disproportional reporting of “syncope” was noted1
–
–
Syncope also was disproportionally reported for 4vHPV
Syncope is a known and labeled adverse event2
 Other PTs signaled but do not represent an adverse event (i.e., drug 
administered to patient of inappropriate age, and other administration 
errors)
 No other disproportional reporting for 9vHPV was noted 
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1 Data provided by FDA/CBER Division of Epidemiology
2 Adverse Effects of Vaccines:  Evidence and Causality, Institute of Medicine, Aug 2011 (http://www.iom.edu/Reports/2011/Adverse-Effects-of-Vaccines-Evidence-and-Causality.aspx)
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Summary of VAERS Review of 9vHPV safety
 VAERS received 7,244 reports following 9vHPV during the study period, 
December 1, 2014 − December 31, 2017
–
–
Most (97%) reports were non-serious
~29 million 9vHPV doses were distributed in the United States
 No new safety signals or unexpected patterns were observed
 The safety profile of 9vHPV is consistent with data from pre-licensure trials and 
post-licensure data on 4vHPV
24
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VSD RCA of 9vHPV: Design and Population
 Prospective cohort
 Surveillance period: 10/4/2015—10/3/2017
 Enrolled in one of 6 participating VSD sites
 Males and females, 9-26 years old
Pre-specified Adverse Events
Adverse event Setting Post-vax window
Primary 
comparison group
Syncope OP, ED, IP Day 0 Concurrent
Injection site rxn, w/ and w/o day 0 OP, ED, IP 0-6, 1-6 days Concurrent
Allergic Reactions OP, ED, IP 0-2 ED, IP 1-2 for OP Concurrent
Seizure ED, IP 0-42 days Concurrent
Anaphylaxis OP, ED, IP 0-2 days Concurrent
Appendicitis ED, IP 1-42 days Historic
Pancreatitis ED, IP 1-42 days Historic
Guillain-Barré Syndrome (GBS) OP, ED, IP 1-42 days Historic
Chronic Inflammatory Demyelinating 
Polyneuropathy (CIDP) OP, ED, IP 1-180 days Historic
Stroke ED, IP 1-42 days Historic
Venous Thromboembolism (VTE) OP, ED, IP 1-42 days Historic
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*Historical  comparison is  based on VSD data from 2007-2014. Concurrent
comparison is based on non-HPV vaccination visits during the surveillance period.
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Summary of findings in VSD RCA for 9vHPV
 Statistical signals occurred for several adverse events after 9vHPV
–
–
Syncope and injection site reactions were expected
All other signals were further investigated
 Signals for allergic reaction, pancreatitis, and appendicitis were not 
confirmed after further evaluation (e.g., diagnosis not verified)
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Example of evaluating a specific outcome: Reports of 
death following HPV vaccine
 Death is the most concerning adverse event
 Frequent misconception that VAERS death reports represent causal 
associations, whereas:
–
–
A report filed to VAERS does not signify that the vaccine was the cause
A VAERS report only indicates a temporal relationship that an adverse 
event occurred sometime after a vaccination
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Mortality Following 4vHPV: VAERS
 Surveillance period:  January 2009-December 2015
 92 reports of death
• 61 hearsay reports: no medical information that could be 
verified
• 2 reports mentioned cause of death but no patient or contact 
information provided
 29 verified reports of death
 VAERS review of confirmed death reports found no pattern 
with respect to:
• Time after vaccination, combination of vaccines administered or 
diagnoses at death
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Mortality Following 4vHPV: VSD
 VSD conducted a study evaluating death among individuals 9-26 years 
from 2005 to 2011
 Medical records and coroners’ reports reviewed
 13 deaths identified within 0-30 days following 4vHPV
• 9 due to external causes; 2 unrelated to vaccination; 2 not sufficient evidence 
to confirm or rule out a causal association
 Rate of death following 4vHPV:  11.7 deaths per 100,000 PY
• US published death rate for all causes among persons 15- 24 years:  67.6 
deaths/100,000 persons
 Risk of death was not increased during 30 days following 4vHPV 
vaccination (case-centered design)
McCarthy et al. Vaccination and 30-day mortality risk in children, adolescents, and young adults.  Pediatrics 2016
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Summary of VAERS and VSD findings on HPV vaccine
 No new safety concerns identified in VAERS or VSD RCA
 Epidemiologic studies in VSD found no increased risks for:
–
–
–
–
autoimmune and neurologic conditions 
venous thromboembolism 
mortality
pregnancy-related conditions
 Studies in progress in VSD:  POTS, CRPS, CFS
POTS: Postural Orthostatic Tachycardia Syndrome
CRPS: Complex Regional Pain Syndrome
CFS: Chronic Fatigue Syndrome
Increasing focus on vaccine safety 
monitoring and research worldwide
Increase in vaccine safety publications
Courtesy of Edwin Asturias
Outcome Selected References Vaccine
Autoimmune and 
neurologic diseasesb
Chao C. J Intern Med 2012
Arnheim-Dahlstrom L. BMJ 2013
Grimaldi-Bensouda L. J Intern Med 2014
Langer-Gould A. JAMA Neurol 2014
Baxter R. Clin Infect Dis 2016
Grimaldi-Bensouda L. J Autoimmun 2017
Sridhar G. Hum Vaccin Immunother 2017
Miranda S. Vaccine 2017
Hviid A. J Intern Med 2018
Frisch M. Int J Epidemiol 2018
Liu EY. CMAJ 2018
4vHPV
4vHPV
4vHPV 
4vHPV
4vHPV
4vHPV
4vHPV
4vHPV
4vHPV
4vHPV
4vHPV
Guillain-Barré syndrome 
only 
Andrews NJ. Vaccine 2017
Gee J. Vaccine 2017 
Deceuninck G. Expert Rev Vaccines 2018 
2vHPV and 4vHPV
4vHPV
4vHPV
Type-1 diabetes only Klein NP. Vaccine 2019 4vHPV
ThromboembolismC Arnheim-Dahlstrom L. BMJ 2013
Scheller NM. JAMA 2014
Naleway AL. Vaccine 2016
Yih WK. Vaccine 2016 
Frisch M. Int J Epidemiol 2018
4vHPV
4vHPV
4vHPV
4vHPV
4vHPV
Multiple outcomesd Gee J. Vaccine 2011 
Klein NP. Arch Pediatr Adolesc Med. 2012
Yih WK. AJE 2018 
Skufca J. Vaccine 2018
Donahue JG. Pediatrics (in press)
4vHPV
4vHPV
4vHPV
2vHPC
9vHPV
Primary ovarian 
insufficiency
Naleway AL. Pediatrics 2018 4vHPV
Chronic fatigue Feiring B. Vaccine 2017
Schurink-Van't Klooster TM. Vaccine 2018
4vHPV
2HPV
Death McCarthy NL.  Pediatrics 2016 4vHPV
Outcomes studied in post-licensure human papillomavirus vaccine 
safety evaluations and selected referencesa
2vHPV, bivalent HPV vaccine; 4vHPV, quadriavlent HPV vaccine; 9vHPV, 9-valent HPV vaccine 
acase series, case reports and reports from passive reporting systems not included; bStudies focused on autoimmune outcomes, demyelinating or other neurologic conditions (most 
included many different outcomes including Guillain-Barré syndrome); cNaleway and Scheller studied only thromboembolism; other studies included many outcomes; dStudies not 
limited to autoimmune or neurologic outcomes Courtesy of Lauri Markowitz
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Conclusions
 Pre-licensure activities form the foundation of vaccine safety
 US has a comprehensive robust vaccine safety monitoring system
–
–
Essential to maintaining public confidence in vaccines
 Science is not sufficient in maintaining acceptance of vaccines
Vaccinate with Confidence: CDC’s strategic framework for 
strengthening vaccine confidence and preventing outbreaks of vaccine 
preventable diseases in the United States
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